Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AS 1409

Next Previous
X
Search
Drug Profile

AS 1409

Alternative Names: Antibody-cytokine fusion drug (AS1409); AS-1409; BC1-IL-12; hBC1-hIL-12; huBC1/IL-12 fusion protein; huBC1/IL12 fusion drug; Tumour-targeting antibody BC1/IL-12 fusion drug

Latest Information Update: 19 Jul 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antisoma; EMD Lexigen
  • Developer Antisoma
  • Class Antibodies; Antineoplastics; Interleukins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interferon gamma stimulants; Natural killer cell stimulants; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in New Zealand (IV)
  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in United Kingdom (IV)
  • 11 Jan 2012 Discontinued - Phase-I for Renal cancer in New Zealand (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top